InsidersTradesSigma
Track the PROTAGONIST THERAPEUTICS, INC. share price and the full directors' dealings record of the company, a listed issuer based in United States. Shares are listed on the US market, under the supervision of SEC (Form 4). Market capitalisation: €9.3bn. The latest transaction was disclosed on 10 August 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: WILLIAM WADDILL. The full history is accessible without an account.
Analysts rate PROTAGONIST THERAPEUTICS, INC. Strong Buy (bullish), based on 13 analysts. Average price target: US$170.38.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
3 of 3 declarations
PROTAGONIST THERAPEUTICS, INC. 是一家生物制药公司，专注于开发免疫和内分泌系统相关疾病的创新疗法。该公司在纳斯达克上市，股票代码为 PTGX。